JUN 30, 2020 6:21 AM PDT

PAR glycohydrolase inhibitors to enhance treatment for gliomas

New hope for glioma patients comes in the form of a novel strategy to target tumors, the results of which are published in Cancer Discovery, a journal of the American Association for Cancer Research. The research was spearheaded by investigators at Massachusetts General Hospital who hope to inform mechanisms that will improve treatment options for the disease. 

While patients with glioma brain tumors can receive surgery, radiation, and chemotherapy, these treatment options do not always offer a cure to the disease. However, past work led by Mass General's Daniel Cahill, MD, Ph.D., Hiroaki Wakimoto, MD, Ph.D., and Julie Miller, MD, Ph.D., demonstrated how mutations in the isocitrate dehydrogenase (IDH) genes have a metabolic Achilles heel. What they found is that mutant IDH genes are particularly susceptible to treatments that lower levels of NAD+, an important metabolic molecule. 

So the researchers combined this knowledge with another key piece of information: chemotherapy activates an enzyme that stimulates NAD+ molecules to unite to produce poly(ADP-ribose), or PAR, which is a key DNA damage signal. And it only does this in IDH mutant glioma cells, not healthy cells. 

Knowing this, the researchers figured this provided the perfect opportunity to target IDH mutant glioma cells by maintaining high PAR levels and low NAD+ levels through chemotherapy.

Gliomas account for about 25% of childhood cancers. Photo: Pixabay

"We found that maximum effectiveness was achieved by combining two agents: temozolomide, the chemotherapy most commonly used to treat patients with IDH mutant gliomas, with a drug that blocks PAR breakdown, known as a PAR glycohydrolase inhibitor," said Dr. Cahill, 

Dr. Wakimoto continues, explaining: "We showed, for the first time, that PAR glycohydrolase inhibitors can be used to enhance the effectiveness of chemotherapy in tumors with metabolic weaknesses in the NAD+ pathway.”

Dr. Miller concludes that their findings have real-life implications for glioma patients. "The long-term significance is that, based on our findings, they could be tested in individuals with IDH mutant gliomas, with a goal of hopefully improving outcomes in these patients," she said.

Sources: Cancer Discovery, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAY 15, 2021
Cancer
What does your polygenic risk score mean?
MAY 15, 2021
What does your polygenic risk score mean?
A study published in The American Journal of Clinical Nutrition recommends that people with a high polygenic risk score ...
MAY 28, 2021
Genetics & Genomics
Some Biofilms Seem to Activate Cancer Genes
MAY 28, 2021
Some Biofilms Seem to Activate Cancer Genes
New research assessed bacterial and fungal biofilms, tenacious microbial communities that are tougher than small groups ...
JUN 14, 2021
Health & Medicine
Another Benefit of Aspirin: Decreased Colorectal Cancer Risk When Started Early
JUN 14, 2021
Another Benefit of Aspirin: Decreased Colorectal Cancer Risk When Started Early
Valued for stroke and heart attack prevention, aspirin is also recommended for colorectal cancer prevention. A Harv ...
JUN 11, 2021
Cancer
Man beats brain cancer with ketogenic diet
JUN 11, 2021
Man beats brain cancer with ketogenic diet
Glioblastoma brain cancer continues to be one of the most fatal cancers, responsible for approximately 15,000 death ever ...
JUL 08, 2021
Genetics & Genomics
Is It Possible to Prevent Leukemia in Down Syndrome Patients?
JUL 08, 2021
Is It Possible to Prevent Leukemia in Down Syndrome Patients?
Children with Down syndrome have a significantly higher likelihood myeloid leukemia occurring in the first five years of ...
AUG 25, 2021
Cell & Molecular Biology
Sino Biological's Listing on the Shenzhen Stock Exchange
AUG 25, 2021
Sino Biological's Listing on the Shenzhen Stock Exchange
China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biot ...
Loading Comments...